Advertisement

Journal of Behavioral Medicine

, Volume 42, Issue 2, pp 291–299 | Cite as

Co-occurring reasons for medication nonadherence within subgroups of patients with hyperlipidemia

  • Dan V. BlalockEmail author
  • Hayden B. Bosworth
  • Bryce B. Reeve
  • Corrine I. Voils
Article

Abstract

Medication nonadherence is a significant clinical problem among individuals taking statins. Poor adherence is often attributable to several reasons, yet most adherence interventions target a single reason. Baseline data were examined from a randomized clinical trial of 236 patients with hyperlipidemia. A latent class analysis was then performed on patients reporting any nonadherence (n = 109). A 4-class solution provided the most optimal fit and differentiation of classes. Class 1 (N = 59, 54%) included patients who reported occasionally forgetting. Class 2 (N = 16, 14%) represented patients who were concerned about side effects. Class 3 (N = 17, 16%) represented patients who reported out-of-routine life events as contributing to nonadherence. Class 4 (N = 17, 16%) represented patients who endorsed a large number reasons indiscriminately. Class membership was almost uniformly unrelated to any patient demographic factors or treatment arm. Each cluster of reasons defining these patients may be best addressed through different intervention strategies.

Keywords

Medication nonadherence Self-report Latent class analysis Reasons 

Notes

Funding

Dr. Blalock was supported by Grant No. TPH 21-000 from the Department of Veterans Affairs Office of Academic Affiliations. Drs. Bosworth and Voils are supported by VA HSR&D Research Career Scientist (RCS) Awards (RCS 08-027 and RCS 14-443, respectively). The study was funded by a VA HSRD grant to Dr. Bosworth (IIR 08-297). This work was also supported by the Center of Innovation for Health Services Research in Primary Care (CIN 13-410) at the Durham VA Medical Center. We thank Felicia McCant, MSW and Susanne Danus, BS for their administrative support.

Compliance with ethical standards

Conflict of interest

Dan V. Blalock, Hayden B. Bosworth, Bryce B. Reeve and Corrine I. Voils declare that they have no conflict of interest.

Human and animal rights and Informed consent

All procedures followed were in accordance with ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.

Supplementary material

10865_2018_9954_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 18 kb)

References

  1. AlGhurair, S. A., Hughes, C. A., Simpson, S. H., & Guirguis, L. M. (2012). A systematic review of patient self-reported barriers of adherence to antihypertensive medications using the World Health Organization Multidimensional Adherence Model. The Journal of Clinical Hypertension, 14, 877–886.CrossRefGoogle Scholar
  2. Blalock, D. B., Zullig, L. L., Bosworth, H. B., Taylor, S., & Voils, C. I. (under review). Self-reported medication nonadherence predicts cholesterol levels, and demonstrates causal priority over time.Google Scholar
  3. Bosworth, H. B., Blalock, D. V., Hoyle, R. H., Czajkowski, S., & Voils, C. I. (in press). The role of psychological science in efforts to improve cardiovascular medication adherence. American Psychologist.Google Scholar
  4. Bosworth, H. B., Olsen, M. K., McCant, F., Stechuchak, K. M., Danus, S., Crowley, M. J., et al. (2018). Telemedicine cardiovascular risk reduction in veterans: The CITIES trial. American Heart Journal, 199, 122–129.CrossRefGoogle Scholar
  5. Brown, I., Sheeran, P., & Reuber, M. (2009). Enhancing antiepileptic drug adherence: A randomized controlled trial. Epilepsy & Behavior, 16, 634–639.CrossRefGoogle Scholar
  6. Choudhry, N. K., Krumme, A. A., Ercole, P. M., Girdish, C., Tong, A. Y., Khan, N. F., et al. (2017). Effect of reminder devices on medication adherence: The REMIND randomized clinical trial. JAMA Internal Medicine, 177, 624–631.CrossRefGoogle Scholar
  7. Eisenberg, D. A. (1998). Cholesterol lowering in the management of coronary artery disease: The clinical implications of recent trials. The American Journal of Medicine, 104, 2S–5S.CrossRefGoogle Scholar
  8. Gadkari, A. S., & McHorney, C. A. (2012). Unintentional non-adherence to chronic prescription medications: How unintentional is it really? BMC Health Services Research, 12, 98–109.CrossRefGoogle Scholar
  9. Gellad, W. F., Thorpe, C. T., Steiner, J. F., & Voils, C. I. (2017). The myths of medication adherence. Pharmacoepidemiology and Drug Safety, 26, 1437–1441.CrossRefGoogle Scholar
  10. Ho, P. M., Bryson, C. L., & Rumsfeld, J. S. (2009). Medication adherence: Its importance in cardiovascular outcomes. Circulation, 119, 3028–3035.CrossRefGoogle Scholar
  11. Ho, P. M., Lambert-Kerzner, A., Carey, E. P., Fahdi, I. E., Bryson, C. L., Melnyk, S. D., et al. (2014). Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: A randomized clinical trial. JAMA Internal Medicine, 174, 186–193.CrossRefGoogle Scholar
  12. Jerant, A., DiMatteo, R., Arnsten, J., Moore-Hill, M., & Franks, P. (2008). Self-report adherence measures in chronic illness: Retest reliability and predictive validity. Medical Care, 46, 1134–1139.CrossRefGoogle Scholar
  13. Kardas, P., Lewek, P., & Matyjaszczyk, M. (2013). Determinants of patient adherence: A review of systematic reviews. Frontiers in Pharmacology4, 91.CrossRefGoogle Scholar
  14. Liberopoulos, E. N., Florentin, M., Mikhailidis, D. P., & Elisaf, M. S. (2008). Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opinion on Drug Safety, 7, 717–725.CrossRefGoogle Scholar
  15. Linzer, D. A., & Lewis, J. B. (2011). poLCA: An R package for polytomous variable latent class analysis. Journal of Statistical Software, 42, 1–29.CrossRefGoogle Scholar
  16. Magidson, J., & Vermunt, J. (2002). Latent class models for clustering: A comparison with K-means. Canadian Journal of Marketing Research, 20, 36–43.Google Scholar
  17. Melnyk, S. D., Zullig, L. L., McCant, F., Danus, S., Oddone, E., Bastian, L., et al. (2013). Telemedicine cardiovascular risk reduction in veterans. American Heart Journal, 165, 501–508.CrossRefGoogle Scholar
  18. Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., et al. (2014). Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews.  https://doi.org/10.1002/14651858.CD000011.pub4.Google Scholar
  19. Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England Journal of Medicine, 353, 487–497.CrossRefGoogle Scholar
  20. Sabaté, E. (Ed.). (2003). Adherence to long-term therapies: Evidence for action. Geneva: World Health Organization.Google Scholar
  21. Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005). Impact of medication adherence on hospitalization risk and healthcare cost. Medical Care, 43, 521–530.CrossRefGoogle Scholar
  22. Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Merz, C. N. B., Blum, C. B., Eckel, R. H., et al. (2014). 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 63(25 Part B), 2889–2934.CrossRefGoogle Scholar
  23. van Driel, M. L., Morledge, M. D., Ulep, R., Shaffer, J. P., Davies, P., & Deichmann, R. (2016). Interventions to improve adherence to lipid-lowering medication. Cochrane Database of Systematic Reviews.  https://doi.org/10.1002/14651858.CD004371.pub4.Google Scholar
  24. Voils, C. I., King, H. A., Neelon, B., Hoyle, R. H., Reeve, B. B., Maciejewski, M. L., et al. (2014). Characterizing weekly self-reported antihypertensive medication nonadherence across repeated occasions. Patient Preference and Adherence, 8, 643–650.CrossRefGoogle Scholar
  25. Voils, C. I., Maciejewski, M. L., Hoyle, R. H., Reeve, B. B., Gallagher, P., Bryson, C. L., et al. (2012). Initial validation of a self-report measure of the extent of and reasons for medication nonadherence. Medical Care, 50, 1013–1019.CrossRefGoogle Scholar
  26. Vrijens, B., De Geest, S., Hughes, D. A., Przemyslaw, K., Demonceau, J., Ruppar, T., et al. (2012). A new taxonomy for describing and defining adherence to medications. British Journal of Clinical Pharmacology, 73, 691–705.CrossRefGoogle Scholar
  27. Yang, C. C. (2006). Evaluating latent class analysis models in qualitative phenotype identification. Computational Statistics & Data Analysis, 50, 1090–1104.CrossRefGoogle Scholar
  28. Zhou, X. H., McClish, D. K., & Obuchowski, N. A. (2009). Statistical methods in diagnostic medicine (Vol. 569). Hoboken: Wiley.Google Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply  2018

Authors and Affiliations

  1. 1.Center for Health Services Research in Primary CareDurham Veterans Affairs Health Care SystemDurhamUSA
  2. 2.Department of Psychiatry and Behavioral SciencesDuke University Medical CenterDurhamUSA
  3. 3.Department of Population Health SciencesDuke University School of MedicineDurhamUSA
  4. 4.School of NursingDuke University Medical CenterDurhamUSA
  5. 5.William S. Middleton Memorial Veterans HospitalMadisonUSA
  6. 6.Department of SurgeryUniversity of Wisconsin-MadisonMadisonUSA

Personalised recommendations